ARS Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
ARS Pharmaceuticals's earnings have been declining at an average annual rate of -43.6%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 128.3% per year.
Key information
-43.6%
Earnings growth rate
-8.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 128.3% |
| Return on equity | -20.8% |
| Net Margin | -8,968.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18
ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Revenue & Expenses Breakdown
How ARS Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -45 | 39 | -2 |
| 31 Mar 24 | 0 | -50 | 43 | 0 |
| 31 Dec 23 | 0 | -54 | 47 | 0 |
| 30 Sep 23 | 0 | -62 | 51 | 0 |
| 30 Jun 23 | 0 | -53 | 39 | 0 |
| 31 Mar 23 | 1 | -42 | 29 | 0 |
| 31 Dec 22 | 1 | -35 | 19 | 0 |
| 30 Sep 22 | 2 | -25 | 10 | 0 |
| 30 Jun 22 | 2 | -25 | 8 | 0 |
| 31 Mar 22 | 4 | -23 | 6 | 0 |
| 31 Dec 21 | 6 | -20 | 5 | 0 |
| 31 Dec 20 | 18 | -1 | 4 | 0 |
Quality Earnings: SPRY is currently unprofitable.
Growing Profit Margin: SPRY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPRY is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.
Accelerating Growth: Unable to compare SPRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPRY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17%).
Return on Equity
High ROE: SPRY has a negative Return on Equity (-20.83%), as it is currently unprofitable.